2 most recent filings and news items mentioning FLGT. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/FLGT/news?limit=20"
Pull FLGT filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayFulgent presented updated data for FID-007 in combination with cetuximab for recurrent/metastatic head and neck cancer, showing 61.9% objective response rate and manageable safety profile as of April 16, 2026. The company plans to advance to Phase 3 studies, which could expand it
View filing at SEC.gov →Fulgent announced interim data from its Phase 2 study of FID-007 combined with cetuximab for recurrent/metastatic head and neck cancer, showing 60% objective response rate and favorable safety profile. The presentation at ASCO 2026 could validate the therapeutic potential of the
View filing at SEC.gov →